Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Day, C.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Amylin analogue as an antidiabetic agent

Caroline Day

Diabetes Group, Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK, cday{at}mededuk.com

The amylin analogue pramlintide (SYMLIN®) is the first in a new class of injectable amylinomimetic agents to be approved for the treatment of diabetes. This adjunct to insulin treatment of type 1 and type 2 diabetes has recently been approved for use in the USA. Pramlintide, unlike native amylin is soluble. It acts mainly via central effects (area postrema) resulting in deceased glucagon secretion, slowing gastric emptying and a satiety effect. It is injected subcutaneously separately from insulin, and usually before each of the main meals. It has been shown to improve glycaemic control without causing weight gain but the dose must be titrated slowly in association with appropriate insulin adjustments to guard against insulin-induced hypoglycaemia and nausea. Thus, pramlintide is an injected amylin replacement therapy that can be used with an insulin regimen to improve glycaemic control without weight gain.

Key Words: amylin • pramlintide • type 1 diabetes • type 2 diabetes • injections.

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 3, 151-154 (2005)
DOI: 10.1177/14746514050050030701
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Diabetes and Vascular Disease ResearchHome page
Early and intensive treatment: glycaemic control in type 2 diabetes
Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 145 - 146.
[PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
C. Day and C. J Bailey
Review: Pharmacological approaches to reduce adiposity
The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 121 - 125.
[Abstract] [PDF]